Asset profile
TLL-018
Small molecule
Evidence outlook · lead readout
NCT05772520 · Plaque Psoriasis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05772520: The study was randomized, triple-blind, and placebo-controlled, but it had small dose-specific groups, including 14 participants in the placebo arm. PASI-75 is a clinical endpoint; although the reported response counts favored the 20-mg and 40-mg doses, statistical significance for the primary comparison was not reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.